Overview
Tirzepatide is an FDA-approved first-in-class dual GIP/GLP-1 receptor agonist peptide that simultaneously activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The addition of GIP receptor agonism to GLP-1R activation produces superior weight loss outcomes compared to GLP-1 monotherapy alone. The SURMOUNT-1 trial demonstrated 20.9% average body weight reduction with tirzepatide 15 mg, surpassing semaglutide results in head-to-head SURMOUNT-5 trial. Approved for T2D (Mounjaro, 2022) and obesity (Zepbound, 2023).
Mechanism of Action
Tirzepatide activates both GIP-R and GLP-1R through complementary pathways. GLP-1R activation in the hypothalamus, pancreas, and periphery drives appetite suppression, incretin insulin secretion, and slowed gastric emptying. GIP-R activation enhances insulin response and appears to reduce some GLP-1 nausea side effects by paradoxical peripheral mechanisms. Together these produce superior reductions in respiratory quotient (RQ), indicating greater fat oxidation versus GLP-1 alone. Tirzepatide shows stronger suppression of lipid synthesis genes (Scd1, Fasn) in liver than semaglutide.
Potential Benefits
- FDA-approved for T2D (Mounjaro) and obesity (Zepbound)
- ~20.9% average body weight reduction in SURMOUNT-1 at 15 mg
- Superior to semaglutide in SURMOUNT-5 head-to-head trial
- Significant HbA1c reduction (2.24% vs semaglutide in SURPASS-2)
- Improved cardiovascular risk factors including blood pressure
- Reduced fatty liver disease markers
- Potential heart failure benefits (SUMMIT trial)
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 2.5-15 mg/week |
| Beginner | 2.5 mg/week for 4 weeks |
| Intermediate | 5-10 mg/week |
| Advanced | 12.5-15 mg/week (FDA-approved max for obesity) |
| Cycle Duration | Ongoing therapeutic; titrate up every 4 weeks as tolerated |
| Cycle Off | Not designed for cycling; weight regain occurs after discontinuation |
FDA titration for Zepbound: 2.5 mg/week → 5 mg (wk 5) → 7.5 mg (wk 9) → 10 mg (wk 13) → 12.5 mg (wk 17) → 15 mg (wk 21). GI side effects typically diminish after titration period.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High
Once-weekly subcutaneous injection; ~80% absolute bioavailability; single-dose auto-injector pen
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Tirzepatide:
Lean Mass Preservation Stack
Aggressive fat loss while preserving lean muscle mass
GH secretagogues help offset the lean mass loss that can accompany significant GLP-1/GIP-driven weight reduction.
Metabolic Syndrome Stack
Comprehensive metabolic correction with mitochondrial support
SS-31 addresses mitochondrial dysfunction associated with metabolic syndrome while Tirzepatide corrects insulin signaling and adiposity.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg auto-injector pens |
|---|---|
| BAC Water | N/A — supplied as pre-mixed solution |
| Storage | Refrigerate at 2-8°C; may store at room temperature (≤30°C) up to 21 days |
| Shelf Life | 24 months unopened; 21 days after removal from refrigeration |
Need exact syringe measurements?
Amino Acid Sequence
Modified GIP/GLP-1 dual agonist with C20 fatty diacid moiety for albumin binding (39 amino acids)
Side Effects & Safety
- Nausea, diarrhea, constipation (most common, dose-dependent)
- Decreased appetite
- Vomiting
- Higher discontinuation rate than semaglutide at high doses
- Lean mass reduction alongside fat loss
- Gallbladder disease risk
Synergistic Compounds
The following compounds have been studied alongside Tirzepatide for potential complementary or synergistic effects:
Learn More
References & Further Reading
- [object Object]
- [object Object]